Cytek Biosciences (CTKB) Shares Outstanding (Diluted Average) (2020 - 2025)

Cytek Biosciences (CTKB) has 6 years of Shares Outstanding (Diluted Average) data on file, last reported at $126.9 million in Q2 2025.

• For the quarter ending Q2 2025, Shares Outstanding (Diluted Average) fell 3.24% year-over-year to $126.9 million; the trailing twelve-month figure through Jun 2025 stood at $126.9 million (down 3.24% YoY), and the FY2023 full-year result was $135.3 million, down 2.37% from the prior year.
• Shares Outstanding (Diluted Average) for Q2 2025 stood at $126.9 million, down from $132.8 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $138.6 million in Q4 2022 and bottomed at $35.9 million in Q2 2021.
• The 5-year median for Shares Outstanding (Diluted Average) is $133.6 million (2022), against an average of $121.2 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) soared 69.93%; it then retreated 3.49% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $81.5 million in 2021, then soared by 69.93% to $138.6 million in 2022, then declined by 2.37% to $135.3 million in 2023, then dropped by 1.85% to $132.8 million in 2024, then retreated by 4.41% to $126.9 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $126.9 million (Q2 2025), $132.8 million (Q3 2024), and $131.2 million (Q2 2024), per Business Quant data.

Peer Comparison